MAY 29, 2019 3:05 AM PDT

Novel Gene Therapy Approved by FDA to Treat Spinal Muscular Atrophy in Pediatric Patients

WRITTEN BY: Dena Aruta

The most common form of spinal muscular atrophy (SMA), a rare genetic disease, is caused by mutations of chromosome 5 in the gene, SMN1. SMN1 encodes for the protein, SMN, which translates to "survival of motor neuron." SMN appears to be responsible for the normal function of motor neurons in the spine that control voluntary muscle activity. Nearby SMN2 genes, depending on the number present, can partially compensate for the lack of SMN1 genes. There is also a rare form that is non-chromosome 5-linked SMA.

The majority of the symptoms these patients experience are related to muscle weakness in muscles near the center of the body (shoulders, thighs, upper back, hip). When the muscles involved in breathing and swallowing are affected, the prognosis is poor, resulting in death before two years of age. Due to the high variability in the age when symptoms begin, chromosome 5 SMA is broken down into four types ranging from mild to severe. Type 1 is seen at birth or in infancy and has the poorest prognosis. Types 2 and 3 develop during childhood and type 4 in teens and adults. Patients who develop SMA later in their teens or adulthood have milder and better motor functioning. The age of onset depends on the amount of functioning SMN the patient has, which correlates with the amount of SMN2 genes; the more functioning SMN, the later the onset.

There are currently no cures for SMA; however, on May 24, 2019, the FDA approved a novel gene therapy drug, Zolgensma, to treat SMA in children under two years of age. It is an adenovector-based gene therapy that targets the SMN1 gene and replaces it with a fully functioning copy into the affected motor neurons.

Figure 1. Example of Adenovector-Related Gene Therapy. Credit: National Human Genome Research Institute

Infants receiving this treatment require a one-time IV dose based on their weight. Its effectiveness has been evaluated in one completed clinical trial and one that is ongoing. Significant improvement in meeting milestones such as the ability to sit up without support has been reported in infants with SMA when compared to those not receiving the treatment.  The most common side effect is liver damage, which has to be monitored for at least three months after the procedure.

The FDA pushed Zolgensma through as a fast track, breakthrough therapy designated as priority review and an orphan drug. It also awarded the manufacturer, AveXis, Inc., with a rare pediatric disease voucher. There are few treatments available for some rare pediatric diseases, and these programs have been set up by the FDA to encourage research to find better treatments or cures for those diseases that currently have few options. 

 

 

About the Author
  • After earning my Bachelor of Science degree in biology/chemistry from Virginia Polytechnic Institute and State University (aka Va. Tech), I went on to complete clinical rotations in laboratory medicine at Roanoke Memorial Hospital. I spent the next 21 years working in healthcare as a clinical microbiologist. In 2015, I combined my fascination with medicine and passion for writing into a freelance career, and I haven't looked back. Even though my expertise is in microbiology and infectious diseases, I'm adept at writing about any medical topic. Being a freelance writer allows me to pursue a career where I can work at home with my two feline assistants, Luke and Grace. I'm a firm supporter of animal rights and volunteer for a local rescue during my free time. 
You May Also Like
MAR 08, 2021
Cell & Molecular Biology
The Cause of Post-Surgical Scarring, Revealed
MAR 08, 2021
The Cause of Post-Surgical Scarring, Revealed
Our bodies can heal many injuries we endure, and while the process often works well, problems can also arise. After abdo ...
MAR 16, 2021
Clinical & Molecular DX
A Blood Test for Predicting if You'll Live to 100
MAR 16, 2021
A Blood Test for Predicting if You'll Live to 100
In 2012, a United Nations report estimated that there are over 316,000 people worldwide over the age of 100. What’ ...
APR 04, 2021
Cell & Molecular Biology
Human Malaria Trial Creates More Questions
APR 04, 2021
Human Malaria Trial Creates More Questions
Malaria is a major health problem in many parts of the world; nearly half a million people die from malaria, and another ...
APR 06, 2021
Health & Medicine
Is There an Upper Limit to the Benefits of Exercise?
APR 06, 2021
Is There an Upper Limit to the Benefits of Exercise?
By now, I am sure that you all know that one of the best ways to improve your health is by running, jogging, walking, or ...
APR 09, 2021
Plants & Animals
Celebrating National Pet Day
APR 09, 2021
Celebrating National Pet Day
Sunday, April 11, is National Pet Day! From pandemic companions to viral videos, pets are a huge part of our lives. Even ...
APR 10, 2021
Drug Discovery & Development
How New ADHD Drug for Children Differs from Adderall
APR 10, 2021
How New ADHD Drug for Children Differs from Adderall
Over 1 in 10 children in the US aged between 5 and 17 have been diagnosed with attention deficit hyperactivity ...
Loading Comments...